The joint detection of Apelin and Vaspin showed a sensitivity of 77.08% and a specificity of 73.77% for forecasting HT in CIS patients after thrombolytic therapy (all P < 0.001). The gene discussed is SERPINA12; the disease is in situ carcinoma.